Motoko Yamaguchi

List of Publications by Citations

80	3,691	30	60
papers	citations	h-index	g-index
86	4,195	4.5	4.58
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
80	Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. *Journal of Clinical Oncology*, **2011**, 29, 4410-6	2.2	416
79	Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. *Blood*, **2007**, 109, 478-85	2.2	323
78	Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. *Journal of Clinical Oncology*, **2009**, 27, 5594-600	2.2	262
77	De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. *Blood*, **2002**, 99, 815-21	2.2	241
76	Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. *Cancer*, **1995**, 76, 2351-6	6.4	225
75	Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. *Journal of Clinical Oncology*, **2008**, 26, 3189-95	2.2	192
74	Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. *Cancer Science*, **2008**, 99, 1016-20	6.9	167
73	Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. *Blood*, **2011**, 118, 6018-22	2.2	127
72	De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. *Haematologica*, **2008**, 93, 1195-202	6.6	102
71	Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. *Blood*, **2018**, 131, 2528-2540	2.2	95
70	Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. *Journal of Clinical Oncology*, **2012**, 30, 4044-6	2.2	93
69	NK-cell neoplasms in Japan. *Hematology*, **2005**, 10, 237-45	2.2	88
68	De Novo CD5+ Diffuse Large B-Cell Lymphomas Express VH Genes With Somatic Mutation. *Blood*, **1998**, 91, 1145-1151	2.2	87
67	Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. *Cancer Science*, **2010**, 101, 1480-6	6.9	83
66	Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan. *Journal of Clinical Oncology*, **2017**, 35, 32-39	2.2	79
65	Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. *Clinical Cancer Research*, **2012**, 18, 4183-90	12.9	69
64	Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases. *Cancer Research*, **2004**, 64, 5948-55	10.1	62

63	PRAD1 gene over-expression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. *British Journal of Haematology*, **1994**, 86, 786-91	4.5	57
62	Gene expression profiling of peripheral T-cell lymphoma including gammadelta T-cell lymphoma. *Blood*, **2009**, 113, 1071-4	2.2	55
61	Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin lymphoma: JCOG 0203 trial. *Journal of Clinical Oncology*, **2011**, 29, 3990-8	2.2	51
60	De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. *British Journal of Haematology*, **1999**, 105, 1133-9	4.5	51
59	Treatment outcome of nasal NK-cell lymphoma: A report of 12 consecutively-diagnosed cases and a review of the literature.. *Journal of Clinical and Experimental Hematopathology: JCEH*, **2001**, 41, 93-99	1.9	42
58	Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. *Cancer Research*, **2003**, 63, 60-6	10.1	41
57	gamma/delta T-cell lymphoma of the thyroid gland. *New England Journal of Medicine*, **1997**, 336, 1391-2	59.2	40
56	Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases. *Pathology International*, **2001**, 51, 747-61	1.8	39
55	Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. *Genes Chromosomes and Cancer*, **2004**, 39, 77-81	5	38
54	Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies. *Cancer Science*, **2003**, 94, 87-91	6.9	34
53	Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. *Thrombosis and Haemostasis*, **2005**, 93, 153-9	7	33
52	Current and future management of NK/T-cell lymphoma based on clinical trials. *International Journal of Hematology*, **2012**, 96, 562-71	2.3	32
51	Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma. *Oncogene*, **2004**, 23, 9148-54	9.2	31
50	Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. *Lancet Oncology, The*, **2020**, 21, 593-602	21.7	27
49	Contrast-enhanced ultrasound examination of lymph nodes in different types of lymphoma. *Cancer Detection and Prevention*, **2006**, 30, 188-91		27
48	Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. *Genes Chromosomes and Cancer*, **2005**, 42, 149-57	5	26
47	Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. *Leukemia and Lymphoma*, **2010**, 51, 813-21	1.9	23
46	Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori. *Gastrointestinal Endoscopy*, **2001**, 54, 92-6	5.2	23

45	Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. *International Journal of Hematology*, **2015**, 102, 188-94	2.3	20
44	Current treatment approaches for NK/T-cell lymphoma. *Journal of Clinical and Experimental Hematopathology: JCEH*, **2017**, 57, 98-108	1.9	19
43	Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. *Best Practice and Research in Clinical Haematology*, **2018**, 31, 315-321	4.2	18
42	Additional t(11;17)(q23;q21) in a patient with Philadelphia-positive mixed lineage antigen-expressing leukemia. *Cancer Genetics and Cytogenetics*, **2001**, 126, 8-12		17
41	De novo CD5-positive diffuse large B-cell lymphoma of the temporal bone presenting with an external auditory canal tumor. *Internal Medicine*, **2006**, 45, 733-7	1.1	15
40	Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. *Cancer Science*, **2014**, 105, 1435-41	6.9	14
39	DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. *Haematologica*, **2020**, 105, 2308-2315	6.6	14
38	Gastric mucosa-associated lymphoid tissue lymphoma with a focal high-grade component diagnosed by EUS and endoscopic mucosal resection for histologic evaluation. *Gastrointestinal Endoscopy*, **2000**, 51, 752-5	5.2	13
37	CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival. *British Journal of Haematology*, **2004**, 125, 180-6	4.5	12
36	Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. *Lancet Haematology,the*, **2018**, 5, e520-e531	14.6	12
35	Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin. *Annals of Hematology*, **2019**, 98, 1647-1655	3	11
34	Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression. *British Journal of Haematology*, **2008**, 142, 562-70	4.5	11
33	MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. *Cancer*, **2017**, 123, 1166-1173	6.4	10
32	Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. *Cancer Science*, **2018**, 109, 2056-2062	6.9	10
31	Hemostatic abnormalities and leukocyte activation caused by infection in patients with malignant lymphoma during chemotherapy. *Thrombosis Research*, **2006**, 117, 671-9	8.2	9
30	Clinicopathologic significance of loss of CD19 expression in diffuse large B-cell lymphoma. *International Journal of Hematology*, **2007**, 85, 41-8	2.3	8
29	Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. *Blood*, **2020**, 136, 2548-2556	2.2	7
28	Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. *European Journal of Haematology*, **2011**, 86, 117-23	3.8	7

27	Successful treatment of lymphoid follicular proctitis with sulfasalazine suppositories. *American Journal of Gastroenterology*, **2000**, 95, 2403-4	0.7	7
26	Expression of interleukin-5 receptors on acute myeloid leukaemia cells: association with immunophenotype and karyotype. *British Journal of Haematology*, **1995**, 91, 169-72	4.5	7
25	JSH practical guidelines for hematological malignancies, 2018: 7. Peripheral T-cell lymphoma (PTCL). *International Journal of Hematology*, **2019**, 109, 137-140	2.3	6
24	Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. *International Journal of Hematology*, **2020**, 111, 686-691	2.3	6
23	Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy. *Journal of Dermatology*, **2005**, 32, 204-9	1.6	6
22	Development of diffuse large cell lymphoma from follicular lymphoma with multiple immunoglobulin heavy chain gene rearrangement occurring in a patient with Wiskott-Aldrich syndrome. *International Journal of Hematology*, **2002**, 76, 196-8	2.3	5
21	Endosonographic images of low-grade lymphoma of mucosa-associated lymphoid tissue after radiotherapy. *Journal of Clinical Gastroenterology*, **2001**, 33, 237-40	3	5
20	Phase I/II Study of Concurrent Chemoradiotherapy for Newly-Diagnosed, Localized Nasal NK/T-Cell Lymphoma: Results of a Phase I Portion of JCOG0211-DI.. *Blood*, **2005**, 106, 2685-2685	2.2	5
19	Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data. *International Journal of Hematology*, **2020**, 112, 807-816	2.3	5
18	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-9. Extranodal NK/T-cell lymphoma, nasal type (ENKL). *International Journal of Hematology*, **2019**, 109, 371-376	2.3	5
17	Reply to A. Chan et al. *Journal of Clinical Oncology*, **2012**, 30, 1016-1017	2.2	4
16	CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region. *International Journal of Hematology*, **2005**, 81, 58-61	2.3	4
15	High Incidence of Asian Variant Intravascular Large B-Cell Lymphoma (IVL) among IVL in Japan: Clinicopathologic Study of 95 Patients.. *Blood*, **2004**, 104, 1365-1365	2.2	3
14	CD19-Negative Diffuse Large B-Cell Lymphoma Shows High Serum LDH Level and Poor Prognosis.. *Blood*, **2005**, 106, 1924-1924	2.2	3
13	Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features. *Cancer Medicine*, **2016**, 5, 1802-9	4.8	3
12	Quantization and similarity measure selection for discrimination of lymphoma subtypes under k-nearest neighbor classification **2004**, 5328, 6		2
11	Pretreatment EBV-DNA Copy Number Is Predictive for Response to SMILE Chemotherapy for Newly-Diagnosed Stage IV, Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of NKTSG Phase II Study. *Blood*, **2010**, 116, 2873-2873	2.2	2
10	S100-positive histiocytes in T-cell-dependent area in human lymph nodes express P-glycoprotein. *Japanese Journal of Cancer Research*, **1994**, 85, 946-51		1

9	Hepatosplenic gammadelta T-cell lymphoma: difficulty in diagnosis. *Internal Medicine*, **2004**, 43, 83-4	1.1	0
8	Topics on the molecular pathogenesis and therapeutic approaches for T/NK-cell lymphoma. *Journal of Clinical and Experimental Hematopathology: JCEH*, **2017**, 57, 85-86	1.9	
7	Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs **2005**, 27, 1241		
6	Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas **2004**, 24, 497		
5	TREATMENT FOR NASAL NK/T-CELL LYMPHOMA. *Japanese Journal of Head and Neck Cancer*, **2004**, 30, 358-362	0.1	
4	Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy. *Blood*, **2019**, 134, 1624-1624	2.2	
3	Evaluation of Central Nervous System Recurrence of Intravascular Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy. *Blood*, **2008**, 112, 4933-4933	2.2	
2	NK-Cell Neoplasms **2013**, 87-103		
1	Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study - JCOG0108A. *Journal of Clinical and Experimental Hematopathology: JCEH*, **2021**, 61, 35-41	1.9	